Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. - Wikidata - awgldk - TriplyDB

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

http://www.wikidata.org/entity/Q48271471

about

Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas Antiangiogenic therapy for high-grade glioma Temozolomide for high grade glioma Biopsy versus resection for the management of low-grade gliomas Awake language mapping for cerebral glioma surgery Image guided surgery for the resection of brain tumours Intra-operative imaging for neuro-oncology Intra-arterial chemotherapy for high-grade gliomas Chemotherapy wafers for high grade glioma Surgical resection and whole brain radiation therapy versus whole brain radiation therapy alone for single brain metastases External beam radiation dose escalation for high grade glioma High-grade glioma management and response assessment-recent advances and current challenges Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR Images Advances in the treatment of newly diagnosed glioblastoma Nonsurgical treatment of recurrent glioblastoma Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade glioma Circulating glioma biomarkers NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods Immunotherapy advances for glioblastoma Medical management of brain tumors and the sequelae of treatment.Modern brain tumor imaging Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2 Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma Emerging methods for disease monitoring in malignant gliomas An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review c-Src and neural Wiskott-Aldrich syndrome protein (N-WASP) promote low oxygen-induced accelerated brain invasion by gliomas Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.Virtual Raters for Reproducible and Objective Assessments in Radiology Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.Recent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma Patients Prospects of immune checkpoint modulators in the treatment of glioblastoma Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

P2860

Q24186964-D04A9AE6-CB9C-4166-98FB-2C700FA05DEE Q24193485-03D1DC0E-2CEC-4E66-95BF-23FE49F69738 Q24197645-FD6307D3-1B41-4D2A-B7F3-AC67314058A0 Q24197750-A4F02FAC-FD54-442A-9BA2-225EA9B8030E Q24200795-DBD3CF44-BDF4-4466-97E6-ACE2C13E7322 Q24200959-EE7C5C70-E1C4-414E-9E0B-B086B490746E Q24201395-33FA17E4-E2C4-4882-90DC-3FC1269C6017 Q24202500-B306378A-510F-4A85-8A80-84043CFB65E2 Q24235641-34CBF74D-0F1F-4A3F-8038-31B8FC2DF81C Q24245168-997963C3-B803-4190-9F52-8FDA7D8B91C6 Q26470382-AD191287-9D49-4B56-B6B6-2A7E74609E47 Q26740664-9C68257A-CFC2-445A-84BB-66394FFBBA89 Q26743358-37C8BD1D-DD9E-495F-9409-151AB009FC11 Q26773514-2CE95DED-ECB8-4054-BDDE-A71BA1C43F22 Q26795560-6DDADA39-F23B-42A2-A13D-F88CD601BD0C Q26796223-D5DCC169-35B3-4332-8CBE-7B0A691A753E Q26801351-6C0D9BA2-386B-46F3-9129-22AAECA6C69F Q26826862-44E9EF69-AC88-497A-9232-BC4CC447AE72 Q26830329-E091D7D9-6031-4C2E-85E1-C1975649A209 Q26830388-D87AE662-E188-40AA-A0E6-CFAFE6F3D364 Q26853308-4B861263-8208-486F-84C7-D001519C0419 Q26853516-5B9612AC-17AC-4438-A795-CFD5FD8695B7 Q26866513-1D00AD65-399E-47DE-AAA4-C6B8572E7480 Q26992174-DA41647D-88EF-4A56-8013-1B08BE43C777 Q27002344-898532C0-991B-4BB9-8443-D33ABA4CB1EF Q27010096-64EBEA1F-2F17-49A9-BD07-25C7663F515F Q27021470-EC218104-FB7A-46CB-95D1-C5FE9C5DF495 Q27023823-C93AF0A7-29BE-49E4-AC58-4E449C919D28 Q27024830-026F8571-1C7E-484C-BC4A-09CD717C876A Q27027730-CF5BD493-690B-4AFE-A7E1-185E6BF3189F Q27305310-AC57B193-DD35-435A-BF50-2BA1251C304B Q27310843-00153CBE-BC6C-4646-AD3E-A0CCA0FC34E8 Q27318743-C715D5FB-E032-4D35-B5A1-1BA91E57A7AD Q27326700-737F6363-44AA-4249-9E1D-8393F2AFC009 Q27344690-D1D1EE82-6565-468D-81C5-9DF083810884 Q27852713-76EFFDEA-BB8F-49A0-A659-A55054CB1F41 Q27853299-33062140-C524-4418-8D4B-BFBA15218EC8 Q28066044-7B99AC91-FA5C-4D32-8435-2AC67139DB7E Q28081371-AEA6C4DC-0C81-4E00-B515-EA4A0E5DB592 Q28083009-5483F381-0641-426F-A5D3-66A28DD302D7

P2860

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

http://www.wikidata.org/entity/Q48271471

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Updated response assessment cr ...... neuro-oncology working group.

@en

Updated response assessment cr ...... neuro-oncology working group.

@nl

type

label

Updated response assessment cr ...... neuro-oncology working group.

@en

Updated response assessment cr ...... neuro-oncology working group.

@nl

prefLabel

Updated response assessment cr ...... neuro-oncology working group.

@en

Updated response assessment cr ...... neuro-oncology working group.

@nl

P1433

Q48271471-45F5DCF1-448E-4402-894B-47E58C675DD2

P1476

Q48271471-B743375C-B079-43F5-B88D-E2E88A08C1C3

P2093

Q48271471-1459DE2D-D2B7-4F11-935C-0DE73ECEF436

Q48271471-2E11F630-CD77-4D59-A676-E44F1980E573

Q48271471-3FA255CC-38FF-4124-A8BD-416CA67F3D58

Q48271471-548A45F1-FBF0-400F-8456-154A73796688

Q48271471-59EDC8BA-54D9-44E7-9136-EC6F70396268

Q48271471-636DA713-2364-475E-B87B-FB9B82D74723

Q48271471-63FF417E-B25F-4CED-BD2B-5BB09F08EED6

Q48271471-6DABB389-DF58-41FA-AB0F-7854A13FC82D

Q48271471-84B25B60-C11A-4484-B3DA-33C3D1EEC096

Q48271471-8CCD7EDE-008E-4A5B-92DB-4CD1DC8C1DE3

P304

Q48271471-90466081-9178-40D1-BE23-66CAB2F3A0AB

P31

Q48271471-5250275E-15B0-45F5-8B11-D9BBF7AA7949

P356

Q48271471-89F2CC8D-582F-4931-B16A-E34E8A8C86E2

P407

Q48271471-D73CD20D-FF89-4152-A8B7-83CB9779E6F5

P433

Q48271471-E94BFADF-7066-422D-AA9B-3AC7E308EDF4

P478

Q48271471-28320290-26A7-4957-97F1-AFB62D6BBF0A

P50

Q48271471-25B72D9F-19BB-4768-A40D-9E0086E24BC0

Q48271471-46CB403D-861A-4FEE-9B2D-8FB2219549DE

Q48271471-683874B6-5562-4EBD-8080-702A193DCC7A

P577

Q48271471-B02D390E-9D13-42D6-8643-7A5BFC7BA3BF

P698

Q48271471-31DCCDDE-11E9-4446-829A-316D85DFC614

P356

JCO.2009.26.3541

P1433

Journal of Clinical Oncology

P1476

Updated response assessment cr ...... neuro-oncology working group.

@en

P2093

A Gregory Sorensen

http://www.w3.org/2001/XMLSchema#string

Andrew B Lassman

http://www.w3.org/2001/XMLSchema#string

Christina Tsien

http://www.w3.org/2001/XMLSchema#string

David R Macdonald

http://www.w3.org/2001/XMLSchema#string

Eric T Wong

http://www.w3.org/2001/XMLSchema#string

John Degroot

http://www.w3.org/2001/XMLSchema#string

Kathleen R Lamborn

http://www.w3.org/2001/XMLSchema#string

Marc C Chamberlain

http://www.w3.org/2001/XMLSchema#string

Mark R Gilbert

http://www.w3.org/2001/XMLSchema#string

Martin J van den Bent

http://www.w3.org/2001/XMLSchema#string

P304

1963-1972

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.26.3541

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

David A Reardon

Evanthia Galanis

P577

2010-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20231676

http://www.w3.org/2001/XMLSchema#string